News

Member Portal

Pounds Return Once Zepbound Users Quit the Weight-Loss Drug

December 11, 2023

FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies.

November 28, 2023

FDA Warns of Rare but Serious Drug Reaction to the Antiseizure Medicines Levetiracetam and Clobazam

November 28, 2023

Benefit Advisors & Employees - Want to know more?

Members: Please call the number on the back of your ID card or e-mail member.services@benecardpbf.com Clients: Contact your Client Relations Manager

By submitting this form, you are consenting to receive marketing emails from: Benecard Services, LLC. (Lawrenceville, NJ 08648), https://www.benecard.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact.

News

Pounds Return Once Zepbound Users Quit the Weight-Loss Drug

LYFGENIA™

CASGEVY™

AVZIVI®

FABHALTA®

JAYPIRCA

FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies.

FDA Warns of Rare but Serious Drug Reaction to the Antiseizure Medicines Levetiracetam and Clobazam

OGSIVEO™

Benefit Advisors & Employees - Want to know more?

Benecard

Newsletter